Definition Visceral Crisis

Conclusion: wPTXÂ +Â BV has achieved favorable efficacy and safety for the treatment of patients with visceral crisis and can therefore be considered as an option for the treatment of this extremely serious clinical disease. A visceral liver attack occurs when bilirubin levels rise very rapidly (>1.5 times the upper limit of normal) without the presence of Gilbert`s syndrome (i.e. Meulengracht syndrome) or obstruction of the bile ducts. CDK4/6 inhibitors can be combined with AI or fulvestrant. Each combination is applicable in de novo metastatic breast cancer and recurrent advanced breast cancer as a first- or second-line treatment, regardless of whether the patient has suffered from primary or secondary endocrine resistance (see ABC definition [3]) and regardless of her menopausal status. Premenopausal patients also require a gonadotropin-releasing hormone (GnRH) agonist. INHIBITION OF CDK4/6 is also an effective treatment for men with advanced breast cancer and should preferably be combined with a GnRH agonist in men. German experts agree with these claims. The German expert group agrees with these ABC5 clarifications of a visceral crisis. The definition of CAT can be adapted accordingly [1]. For metastatic breast cancer, various medical treatment options are available; The individual indication depends, among other things, on the biology of the tumor and the pressure of treatment.

There is a great need for treatment, for example, in the case of a visceral seizure. According to the ABC5 panelists, this is defined as severe organ dysfunction, which leads to severe symptoms and rapid progression of the disease, and can also be assessed using laboratory values. Visceral crisis is a serious dysfunction of an organ that requires rapidly effective treatment. wPTXÂ +Â BV can be considered as an option for breast cancer patients with a visceral crisis. Visceral crisis in metastatic breast cancer (CBM) is defined as a serious dysfunction of an organ that requires rapidly effective treatment. Although weekly paclitaxel plus bevacizumab (wPTX +Â BV) achieves a high response rate to negative human epidermal growth factor receptor 2 (HER2) MBC, the efficacy and safety of wPTXÂ+Â BV in visceral seizures is unclear. A visceral seizure of the lungs can be assumed if dormant dyspnea increases faster and cannot be relieved by pleural drainage (Evidence Level [LoE]: Gutachten/NA). According to the ABC5 consensus, evidence of visceral metastases alone is not sufficient to define a visceral seizure. On the contrary, vital organs must be so severely impaired that the use of timely and reliable therapies is necessary.

The ABC5 consensus describes a visceral crisis of the liver and lungs as follows: The effectiveness of chemotherapy in visceral seizures is unclear. We retrospectively examined patients with MBC with visceral crisis who received wPTXÂ +Â BV. Visceral crisis was defined as: hepatic impairment (aspartate or alanine aminotransferase >200 U/L or total bilirubin >1.5 mg/dl), respiratory dysfunction (carcinomatic lymphangiomatosis, SpO2 <93% in ambient air or thoraceresis required), superior vena cava syndrome (CVS) or bone marrow carcinomatosis. The primary endpoint was the proportion of patients treated with wPTXÂ +Â BV after 12 weeks. We also looked at the timing of treatment failure (TTF), overall survival (OS), objective response rate (ORR) and adverse events. Atezolizumab/nab-paclitaxel is the first immunotherapy/chemotherapy combination available for the first-line treatment of patients with metastatic expression (ER, PR and HER2) and -L1 in immune cells (-L1/CI ≥1%, evaluated with ventana SP142 antibody) [1]. Ninety-five percent (94.8%) of ABC5 panelists consider atezolizumab/NAB paclitaxel as a first-line treatment option in advanced L1/CI+ ASSDC (MCBS 3; LoE/GoR: I/B). In the pivotal Phase III study IMpassion-130 [36], the combination achieved significantly prolonged progression-free survival in patients with advanced L1+NDCC (HR 0.62; p < 0.0001) compared to chemotherapy alone (nab-paclitaxel).

PFS was the primary endpoint of the study. Final survival data are not yet available. At the time of evaluation, a numerical survival advantage in favour of atezolizumab (HR = 0.62) was observed [36]. Johannes Ettl received honoraria from Astra Zeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, TEVA and travel assistance from Celgene, Lily, Novartis, Pfizer, TEVA and Pierre Fabre. Leptomeningeal disease is a rare but serious form of metastatic spread that can lead to pronounced neurological complications. There is currently no uniform procedure for this situation. In addition to the best supportive care, radiation or chemotherapy are possible treatment options according to the ABC5 consensus. The treatment decision should be made by an interdisciplinary team (tumor board) taking into account the prognosis (LoE/GoR: expert opinion). Abc5 panelists recommend focal radiation therapy for clearly defined, specifically symptomatic lesions. Whole brain radiation therapy may be considered for extensive nodular or symptomatic leptomeningeal diseases (loE/GoR: expert opinion). German experts agree. From a German point of view, breast examinations – if necessary with subsequent imaging – are usually part of staging in patients with stable disease [1].

The reason for this is the loco-regional evaluation. Possible secondary tumors that may have a different tumor biology should be detected at an early stage so that treatment can be adapted in time. Predictive factors for the treatment of metastatic breast cancer according to the 2019 AGO recommendation version 1.0 [1] The ABC5 conference is a platform for important discussions on the latest developments in advanced and metastatic breast cancer. The ABC Consensus makes an important contribution to the standardization of advanced breast cancer treatment internationally and the optimization of treatment worldwide. The ABC conference is therefore complementary to the St. Gallen Consensus Conference on Early Breast Cancer. The next ABC6 consensus conference will take place from 4 to 6 November 2021 in Lisbon, Portugal. The ABC5 panelists and the German expert group are aware that not all cancer patients in all countries of the world have unlimited access to morphine preparations. Access to adequate pain control and morphine preparations must be established worldwide.

Overall, the results of the ABC5 vote clearly show that CDK4/6 inhibitors are now part of routine clinical practice and are accepted as standard treatment. German experts point out that the use of endocrine combination therapy based on CDK4/6 inhibitors should be discussed with patients with advanced HR+/HER2 breast cancer. Statements submitted to the field vote in Lisbon were rated „yes“ (approval), „no“ (rejection) or „abstention“ by the panelists. In addition, there was also the possibility of voting on „data deficient“. This option can be selected if a panel member believes that the available data is not sufficient for a yes or no vote. The ABC5 consensus assessment system is based on the ESMO treatment guidelines [7] (Table 1). In the randomized phase III solar-1 study, the median progression-free survival of postmenopausal patients with advanced MUTATED HR+/HER2-PIK3CA breast cancer was reduced by approximately. 5 months and therefore almost doubled (HR = 0.65; p < 0.001) using the PI3K alpelisib inhibitor in combination with fulvestrant [28]. All patients included disease progression after previous endocrine therapy. Progression-free survival was the primary endpoint of the study.

Nevertheless, nearly 90% (87.8%) of ABC5 panelists consider the combination of allpelisib/fulvestrant as a treatment option for postmenopausal patients with HR+/HER2 – metastatic breast cancer – even before approval; The prerequisite is that there is a PIK3CA mutation on exon 9 or 20 and the patient has already been treated with AI and has sufficient HbA1C levels. However, the ABC5 panelists point out that given the spectrum of side effects of allpélisib (treatment-induced risk of diabetes mellitus) and the fact that no survival benefit has yet been demonstrated for the combination, the treatment decision needs to be subject to a particularly rigorous benefit-benefit assessment.